Indication
Childhood Absence Epilepsy
6 clinical trials
3 products
Product
BrivaracetamClinical trial
A MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY TO EVALUATE LONG-TERM SAFETY AND TOLERABILITY OF BRIVARACETAM IN STUDY PARTICIPANTS WITH CHILDHOOD ABSENCE EPILEPSY OR JUVENILE ABSENCE EPILEPSYStatus: Not yet recruiting, Estimated PCD: 2029-02-28
Clinical trial
A Randomized, Dose-Finding and Confirmatory, Double-Blind, Placebo-Controlled, Parallel-Group Multicenter Study With a 2 Stage Adaptive Design and Randomized Withdrawal to Evaluate the Efficacy, Safety, and Tolerability of Brivaracetam as Monotherapy in Patients 2 to 25 Years of Age With Childhood Absence Epilepsy or Juvenile Absence EpilepsyStatus: Recruiting, Estimated PCD: 2026-02-25
Clinical trial
A Multicenter, Open-Label, Single-Arm Study to Evaluate Long-Term Safety, Tolerability, and Efficacy of Brivaracetam in Study Participants 2 to 26 Years of Age With Childhood Absence Epilepsy or Juvenile Absence EpilepsyStatus: , Estimated PCD: 2024-09-27
Product
CannabidiolClinical trial
A Multicenter, Open-Label, Flexible Dose Study to Assess the Long-Term Safety of Pharmaceutical Grade Synthetic Cannabidiol Oral Solution in Pediatric Patients With Treatment-Resistant Childhood Absence SeizuresStatus: Terminated, Estimated PCD: 2019-06-24
Clinical trial
A Phase 2, Open-label, Dose-finding Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of Pharmaceutical Grade Synthetic Cannabidiol Oral Solution in Pediatric Patients With Treatment-Resistant Childhood Absence SeizuresStatus: Terminated, Estimated PCD: 2019-05-15
Clinical trial
Flunarizine for Treatment Resistant Absence EpilepsyStatus: Terminated, Estimated PCD: 2023-05-26
Product
Flunarizine